Perceptive Advisors substantially increased its position in Celcuity Inc. during the fourth quarter of 2025, acquiring 203,881 shares valued at approximately $16.76 million. The investment elevated the biotech-focused fund's stake to 5.62% of assets under management, establishing Celcuity as the fund's second-largest holding and signaling institutional confidence in the company's clinical and commercial prospects.
Celcuity's stock has experienced significant appreciation, gaining approximately 700% over the past 12 months. The surge reflects investor optimism surrounding the anticipated FDA approval of Gedatolisib, the company's lead therapeutic candidate. The drug is currently under regulatory review with a Priority User Fee Act (PDUFA) goal date of July 17, 2026, positioning a potential decision within the coming months.
The timing and scale of Perceptive Advisors' investment—a firm specializing in biotech and life sciences ventures—suggests expectations of meaningful near-term catalysts. Regulatory approval of Gedatolisib would represent a pivotal milestone for the clinical-stage company, with significant implications for shareholder value and the company's transition toward commercialization.